Literature DB >> 11001129

Short course antibiotic therapy for respiratory infections: a review of the evidence.

M E Pichichero1.   

Abstract

BACKGROUND: The judicious use of antibiotics entails achieving the appropriate balance between prescribing them with sufficient frequency and duration to effect a clinical cure for bacterial infections and overprescribing them, a practice that increases prescription drug costs as well as the risks of bacterial resistance, noncompliance with therapy and side effects. The recognition that the traditional 10-day or greater duration of therapy for acute otitis media, tonsillopharyngitis and sinusitis does not derive from a strong scientific or medical rationale (with the exception of penicillin therapy for tonsillopharyngitis) and the increasing awareness of the adverse sequelae of long-duration antibiotic therapy have led some clinicians to call for shortening the duration of antibiotic therapy in these infections. The soundness of this recommendation hinges on the demonstration that shortened courses of antibiotic therapy are at least as effective as traditional courses of therapy. SYNOPSIS: Data relevant to determining the optimum duration of therapy in acute otitis media, tonsillopharyngitis and sinusitis are reviewed in this article. The review demonstrates particularly strong justification for shortening the duration of therapy from the standard 10 days to 5 days in acute otitis media, in which numerous open label and controlled studies have shown equivalent efficacy of the two durations of regimen. A growing body of evidence indicates that tonsillopharyngitis, too, can be effectively treated with non-penicillin antibiotics given for fewer than 10 days. Although sinusitis data are less plentiful than those for acute otitis media and tonsillopharyngitis, the results available to date are encouraging in suggesting that shortened courses of therapy may also be appropriate for acute maxillary sinusitis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11001129     DOI: 10.1097/00006454-200009000-00037

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  6 in total

1.  Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.

Authors:  Joseph D'Ignazio; Marco A Camere; Drew E Lewis; Daniel Jorgensen; Jeanne D Breen
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

2.  Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.

Authors:  Sanjay Sethi; John Breton; Brian Wynne
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 3.  Short-course therapy for community-acquired pneumonia in paediatric patients.

Authors:  Shamim Qazi
Journal:  Drugs       Date:  2005       Impact factor: 9.546

4.  A pilot study of single-dose azithromycin versus three-day azithromycin or single-dose ceftriaxone for uncomplicated acute otitis media in children.

Authors:  Adriano Arguedas; Cecilia Loaiza; Alexandra Perez; Alvaro Gutierrez; Marco Luis Herrera; Constance D Rothermel
Journal:  Curr Ther Res Clin Exp       Date:  2003

Review 5.  Shortened course of antibacterial therapy for acute otitis media.

Authors:  Philippe Ovetchkine; Robert Cohen
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 6.  Responsible prescribing for upper respiratory tract infections.

Authors:  J Turnidge
Journal:  Drugs       Date:  2001       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.